var data={"title":"Sunitinib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sunitinib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/209001?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sunitinib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sunitinib: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10432264\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Hepatotoxicity has been observed in clinical trials and postmarketing experience. Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525534\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Sutent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5558623\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Sutent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525538\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Tyrosine Kinase Inhibitor;</li>\n      <li>\n        Antineoplastic Agent, Vascular Endothelial Growth Factor (VEGF) Inhibitor;</li>\n      <li>\n        Vascular Endothelial Growth Factor (VEGF) Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2526125\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastrointestinal stromal tumor (GIST):</b> Oral: 50 mg once daily for 4 weeks of a 6-week treatment cycle (4 weeks on, 2 weeks off) (Demetri 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>GIST off-label dosing:</i> Oral: 37.5 mg once daily, continuous daily dosing (George 2009a)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pancreatic neuroendocrine tumors, advanced (PNET):</b> Oral: 37.5 mg once daily, continuous daily dosing (Raymond 2011); the maximum daily dose used in clinical trials was 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal cell cancer, adjuvant treatment:</b> Oral: 50 mg once daily for 4 weeks of a 6-week treatment cycle (4 weeks on, 2 weeks off) for 9 cycles (Ravaud 2016); the minimum daily dose used in clinical trials was 37.5 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal cell cancer, advanced:</b> Oral: 50 mg once daily for 4 weeks of a 6-week treatment cycle (4 weeks on, 2 weeks off) (Motzer 2006a; Motzer 2006b; Motzer 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Soft tissue sarcoma, non-GIST (off-label use):</b> Oral: 37.5 mg once daily, continuous daily dosing (George 2009b)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroid cancer, refractory (off-label use):</b> Oral: 50 mg once daily for 4 weeks of a 6-week treatment cycle (4 weeks on, 2 weeks off) (Cohen, 2008; Ravaud, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Dosage adjustment with concurrent strong CYP3A4 inhibitor:</i> Avoid concomitant administration with strong CYP3A4 inhibitors (eg, ketoconazole); if concomitant administration with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction to a minimum of 37.5 mg/day (GIST, RCC) or 25 mg/day (PNET).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Dosage adjustment with concurrent CYP3A4 inducer:</i> Avoid concomitant administration with CYP3A4 inducers (eg, rifampin); if concomitant administration with a CYP3A4 inducer cannot be avoided, consider a dosage increase (with careful monitoring for toxicity) to a maximum of 87.5 mg/day (GIST, RCC) or 62.5 mg/day (PNET).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2526126\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2526127\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;30 mL/minute: No initial adjustment required; subsequent adjustments may be needed based on safety and tolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute (not on hemodialysis): No initial adjustment required; subsequent adjustments may be needed based on safety and tolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ESRD on hemodialysis: No initial adjustment required; subsequent dosage <b>increases</b> (up to twofold) may be required due to reduced (47%) exposure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2526128\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pre-existing hepatic impairment: No adjustment is necessary with mild-to-moderate (Child-Pugh class A or B) hepatic impairment; not studied in patients with severe (Child-Pugh class C) hepatic impairment. Studies excluded patients with ALT or AST &gt;2.5 x ULN, or if due to liver metastases, ALT or AST &gt;5 x ULN.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatotoxicity during treatment: Hepatic adverse events &ge; grade 3 or 4: Withhold treatment; discontinue if hepatotoxicity does not resolve. Do not reinitiate in patients with severe changes in liver function tests or other signs/symptoms of liver failure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6825472\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">Dosage modifications should be done in increments or decrements of 12.5 mg; individualize based on safety and tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac toxicity:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ejection fraction &lt;50% but &gt;20% below baseline or below the lower limit of normal (if baseline ejection fraction is not available) without evidence of CHF: Interrupt treatment and/or reduce dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clinical signs/symptoms of HF: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic toxicity:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Signs/symptoms of erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), including progressive skin rash, often with blisters or mucosal lesions: Discontinue sunitinib; do not restart treatment if SJS or TEN are suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Necrotizing fasciitis: Discontinue sunitinib.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypertension, severe: Temporarily interrupt treatment until hypertension is controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nephrotic syndrome: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proteinuria:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Urine protein &ge;3 g/24 hours: Interrupt treatment and reduce the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Persistent urine protein &ge;3 g/24 hours despite dose reductions: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reversible posterior leukoencephalopathy (RPLS): Temporarily withhold treatment; after resolution, may resume with discretion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombotic microangiopathy: Discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2526134\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sutent: 12.5 mg, 25 mg, 37.5 mg, 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525536\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10437825\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM219111.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68jdroIn6OcNeNaWAWUVFFAw==&amp;TOPIC_ID=10305\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM219111.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2526129\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered with or without food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132824\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525541\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastrointestinal stromal tumor:</b> Treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pancreatic neuroendocrine tumors, advanced:</b> Treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal cell carcinoma:</b> Adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy; treatment of advanced RCC</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25470558\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Thyroid cancer; Soft tissue sarcoma (non-GIST)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3402058\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">SUNItinib may be confused with axitinib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, PAZOPanib, regorafenib, SORAfenib, vandetanib</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dosing schedules vary by indication; some treatment regimens are continuous daily dosing; other treatment schedules are daily dosing for 4 weeks of a 6-week cycle (4 weeks on, 2 weeks off)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525552\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (27% to 34%, GIST: 8% to 15%; grade 3: 10% to 13%, GIST: 4%), decreased left ventricular ejection fraction (RCC: 16% to 27%, grade 3: 3% to 7%; GIST: 11%, grade 3: 1%), peripheral edema (RCC: 24%), chest pain (RCC: 13%), severe hypertension (4% to 10%; &gt;200 mmHg systolic or 110 mmHg diastolic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (RCC: 62%, pNET: 33%), glossalgia (pNET: &le;48%; RCC: 11%), mouth pain (pNET: &le;48%; RCC: 6% to 14%), headache (18% to 23%), insomnia (15% to 18%), chills (RCC: 14%), depression (RCC: 11%), dizziness (RCC: 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin discoloration (&le;25% to 30%; yellow color), hair discoloration (20% to 29%; GIST: 7%), palmar-plantar erythrodysesthesia (23% to 29%, GIST: 14%; grades 3/4: 4% to 8%), xeroderma (15% to 23%), skin rash (14% to 18%; RCC: 29%), alopecia (5% to 14%), erythema (RCC: 12%), pruritus (RCC: 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased uric acid (RCC: 46%), decreased serum calcium (34% to 42%), decreased serum albumin (pNET: 41%, RCC: 28%), decreased serum phosphate (31% to 36%), increased serum glucose (RCC: 23%), decreased serum potassium (12% to 21%), decreased serum sodium (RCC: 20%), decreased serum magnesium (pNET: 19%), increased serum potassium (16% to 18%), hypothyroidism (4% to 7%; RCC: 16%), increased serum calcium (RCC: 13%), increased serum sodium (10% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (59% to 66%; GIST: 40%), nausea (RCC: 58%; pNET: 45%), increased serum lipase (17% to 25%; RCC: 56%; grades 3/4: 5% to 18%), anorexia (RCC: 48%; GIST: 33%), mucositis (47% to 48%, GIST: 29%; includes aphthous stomatitis, dry mucous membranes, gingival pain, gingivitis, glossitis, oral discomfort, oral mucosal ulcer, stomatitis, tongue ulceration), dysgeusia (21%; RCC: 47%), vomiting (34% to 39%), abdominal pain (30% to 39%), increased serum amylase (17% to 20%; RCC: 35%; grades 3/4: 4% to 6%), dyspepsia (RCC: 34%; pNET: 15%), constipation (20% to 23%), weight loss (16%), flatulence (RCC: 14%), xerostomia (RCC: 13%), gastroesophageal reflux disease (RCC: 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased hemoglobin (RCC: 79%, pNET: 65%, GIST: 26%; grades 3/4: &le;8%), leukocyte disorder (decreased leukocytes; RCC: 78%; grades 3/4: 8%), decreased neutrophils (71% to 77%, GIST: 53%; grades 3/4: 10% to 17%), abnormal absolute lymphocyte count (decreased; RCC: 68%, pNET: 56%, GIST: 38%; grades 3/4: RCC: 18%, pNET: 7%), decreased platelet count (60% to 68%, GIST: 38%, GIST and RCC: grades 3/4: 5% to 9%), hemorrhage (18% to 22%; RCC: 37%; RCC and GIST, grades 3/4: 3% to 4%; includes hematemesis, hematochezia, hematoma, hemoptysis, melena, metrorrhagia)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (pNET: 72%, RCC: 56%, GIST: &le;39%; grades 3/4: &le;2% to 5%), increased serum ALT (pNET: 61%; RCC: 51%; GIST: &le;39%; grades 3/4: &le;2% to 4%), increased serum alkaline phosphatase (RCC: 46%; GIST: 24%; grades 3/4: 2% to 4%), increased serum bilirubin (16% to 20%; pNET: 37%; RCC and GIST, grades 3/4: 1%), increased indirect serum bilirubin (RCC and GIST: 10% to 13%;  grades 3/4: &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase (RCC: 49%), limb pain (RCC: 40%; GIST: &le;14%), weakness (22% to 34%), arthralgia (RCC: 30%; pNET: 15%), back pain (RCC: 28%), myalgia (GIST: &le;14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (RCC: 70%; GIST: 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (RCC: 27%), dyspnea (RCC: 26%), epistaxis (pNET: 20%), nasopharyngitis (RCC: 14%), oropharyngeal pain (RCC: 14%), upper respiratory tract infection (RCC: 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (RCC: 22%)</p>\n    <p style=\"text-indent:0em;margin-left:0em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Deep vein thrombosis (&le;3%), pulmonary embolism (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypoglycemia (2%; pNET: 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Hemorrhoids (RCC: 10%), pancreatitis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (RCC: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute renal failure, adrenocortical insufficiency, arterial thrombosis (includes cerebral infarction, cerebrovascular accident, transient ischemic attack), cardiac failure, cardiomyopathy, cerebral hemorrhage, cholecystitis (particularly acalculous), erythema multiforme, esophagitis, fistula (sometimes associated with tumor necrosis and/or regression), fulminant necrotizing fasciitis (including of the perineum), gastrointestinal hemorrhage, gastrointestinal perforation, hemolytic uremic syndrome, hepatic failure, hepatotoxicity, hypersensitivity (includes angioedema), hyperthyroidism, ischemic heart disease, myocardial infarction, myopathy (with/without acute renal failure), nephrotic syndrome, neutropenic infection, osteonecrosis of the jaw, preeclampsia (like syndrome with proteinuria and reversible hypertension) (Gallucci 2013; Patel 2008), prolonged Q-T interval on ECG (dose dependent), proteinuria, pulmonary hemorrhage, pyoderma gangrenosum (including positive dechallenges), renal insufficiency, respiratory tract hemorrhage, respiratory tract infection (may be serious), reversible posterior leukoencephalopathy syndrome, rhabdomyolysis (with/without acute renal failure), seizure, sepsis, septic shock, skin infection (may be serious), Stevens-Johnson syndrome, thrombotic thrombocytopenic purpura, thyroiditis (Feldt 2012), torsades de pointes, toxic epidermal necrolysis, tumor hemorrhage, tumor lysis syndrome, urinary tract hemorrhage, urinary tract infection (may be serious), ventricular arrhythmia, wound healing impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525548\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canadian labeling: Hypersensitivity to sunitinib or any component of the formulation; pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525549\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: Cardiovascular events (some fatal), including heart failure (HF), cardiomyopathy, myocardial ischemia and myocardial infarction (MI) have been reported. Consider left ventricular ejection fraction (LVEF) baseline evaluation prior to treatment in patients without cardiac risk factors; monitor closely for signs/symptoms of HF during sunitinib treatment; consider periodic LVEF evaluations. Discontinue with clinical signs and symptoms of HF. In patients without clinical signs/symptoms of HF, interrupt therapy and/or decrease dose with LVEF &lt;50% but &gt;20% from baseline or below the lower limit of normal (if baseline ejection fraction is not available). In some patients, HF may recover. Patients with cardiac events (MI [including severe/unstable angina], bypass graft, symptomatic HF, cerebrovascular accident, transient ischemic attack, and pulmonary embolism) within the previous 12 months were excluded from clinical trials, and it is not known if the risk for left ventricular dysfunction is increased in patients with these conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicities: Severe cutaneous reactions, including erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have been reported (some fatal); if signs/symptoms of EM, SJS, or TEN (progressive skin rash, often with blisters or mucosal lesions) are present, discontinue sunitinib. Do not restart treatment if SJS or TEN are suspected. Necrotizing fasciitis (with fatalities) has been reported, including perineum necrotizing fasciitis and fasciitis secondary to fistula formation. Discontinue sunitinib in patients who develop necrotizing fasciitis. Sunitinib may cause skin and/or hair depigmentation or discoloration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI complications: Serious and fatal GI complications, including GI perforation, have occurred (rarely) in patients with intra-abdominal malignancies. Pancreatitis has been observed in RCC patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hand-foot skin reaction: Hand-foot skin reaction (HFSR) observed with tyrosine kinase inhibitors (TKIs), including sunitinib, and is distinct from hand-foot syndrome (palmar-plantar erythrodysesthesia) associated with traditional chemotherapy agents; HFSR due to TKIs is localized with defined hyperkeratotic lesions; symptoms include burning, dysesthesia, paresthesia, or tingling on the palms/soles, and generally occur within the first 2 to 4 weeks of treatment; pressure and flexor areas may develop blisters (callus-like), dry/cracked skin, edema, erythema, desquamation, or hyperkeratosis (Appleby 2011). The following treatments may be used in addition to the recommended dosage modifications (Lacouture 2008). Prior to treatment initiation, a pedicure is recommended to remove hyperkeratotic areas/calluses, which may predispose to HFSR; avoid vigorous exercise/activities that may stress hands or feet. During therapy, patients should reduce exposure to hot water (may exacerbate hand-foot symptoms); avoid constrictive footwear and excessive skin friction. Patients may also wear thick cotton gloves or socks and should wear shoes with padded insoles. Grade 1 HFSR may be relieved with moisturizing creams, cotton gloves and socks (at night) and/or keratolytic creams such as urea (20% to 40%) or salicylic acid (6%). Apply topical steroid (eg, clobetasol ointment) twice daily to erythematous areas of grade 2 HFSR; topical anesthetics (eg, lidocaine 2%) and then systemic analgesics (if appropriate) may be used for pain control. Resolution of acute erythema may result in keratotic areas which may be softened with keratolytic agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhage: Hemorrhagic events (some fatal) have been reported through postmarketing surveillance. Events (including grades 3 and 4 toxicity) have included GI, respiratory, tumor, urinary tract, and brain hemorrhages. Epistaxis was the most commonly observed hemorrhagic event, while GI hemorrhage was the most common &ge; grade 3 event. Tumor-related hemorrhage has been reported, and may occur suddenly. In patients with pulmonary tumors, severe and life-threatening hemoptysis or pulmonary hemorrhage may occur; cases of pulmonary hemorrhage with some fatalities have been reported. Monitor for signs/symptoms of bleeding/hemorrhage and obtain complete blood counts as clinically necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: <b>[US Boxed Warning]: Hepatotoxicity, which may be severe and/or fatal, has been observed in clinical trials and in postmarketing surveillance.</b> Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended. Signs of liver failure include jaundice, elevated transaminases, and/or hyperbilirubinemia, in conjunction with encephalopathy, coagulopathy and/or renal failure. Monitor liver function tests at baseline, with each treatment cycle and if clinically indicated. Withhold treatment for grade 3 or 4 hepatotoxicity; discontinue if hepatotoxicity does not resolve. Do not reinitiate in patients with severe changes in liver function tests or other signs/symptoms of liver failure. Sunitinib has not been studied in patients with ALT or AST &gt;2.5 times ULN (or &gt;5 times ULN if due to liver metastases).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Sunitinib may cause hypertension; for severe hypertension, interrupt therapy until hypertension is controlled. Monitor blood pressure routinely during sunitinib treatment; if indicated, initiate appropriate antihypertensive treatment to reduce the risk for cardiotoxicity (Armenian 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoglycemia: Symptomatic hypoglycemia has been associated with sunitinib; may result in loss of consciousness or require hospitalization. Hypoglycemia occurred infrequently in patients with renal cell cancer and gastrointestinal stromal tumors (GIST); however, the incidence is higher (~10%) in patients with pancreatic neuroendocrine tumors (PNET); preexisting glucose homeostasis abnormalities were not always present in hypoglycemic patients with PNET. Blood glucose decreases may be worse in patients with diabetes. Monitor blood glucose levels regularly during and following discontinuation of treatment. Dose modifications of antidiabetic medications may be necessary to minimize the risk of hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported with sunitinib. Concurrent bisphosphonate use or dental disease may increase the risk for ONJ. According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), MRONJ has been associated with bisphosphonates and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy. Antiangiogenic agents, when given concomitantly with antiresorptive agents, are associated with an increased risk of ONJ. Other risk factors for MRONJ include dentoalveolar surgery (eg, tooth extraction, dental implants), preexisting inflammatory dental disease, and concomitant corticosteroid use. Consider a dental examination and preventive dentistry prior to initiation of sunitinib (and during therapy); if possible, avoid invasive dental procedures in patients with current or prior bisphosphonate use (particularly IV bisphosphonate use). The AAOMS suggests that if medically permissible, initiation of antiangiogenic agents for cancer therapy should be delayed until optimal dental health is attained (if extractions are required, antiangiogenesis therapy should delayed until the extraction site has mucosalized or until after adequate osseous healing). Once antiangiogenic therapy for oncologic disease is initiated, procedures that involve direct osseous injury and placement of dental implants should be avoided. Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proteinuria/nephrotic syndrome: Proteinuria and nephrotic syndrome have been reported; some cases have led to renal failure and fatal outcomes. Monitor for new onset or worsening proteinuria with baseline and periodic urinalysis and follow up with 24-hour urine protein if clinically indicated. If urine protein is &ge;3 g/24 hours, interrupt treatment and reduce the dose. Discontinue treatment in patients with nephrotic syndrome or persistent urine protein &ge;3 g/24 hours despite dose reductions. The safety of continuing treatment with sunitinib in patients with moderate to severe proteinuria has not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QTc prolongation: QTc prolongation and torsade de pointes have been observed (dose dependent); use caution in patients with a history of QTc prolongation, with medications known to increase sunitinib levels or prolong the QT interval, or patients with preexisting (relevant) cardiac disease, bradycardia, or electrolyte imbalance. Consider baseline and periodic 12-lead ECGs; correct electrolyte abnormalities prior to treatment and monitor and correct potassium, calcium, and magnesium levels during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Reversible posterior leukoencephalopathy syndrome: Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported rarely (some fatal). Symptoms of RPLS include confusion, headache, hypertension, lethargy, seizure, blindness and/or other vision, or neurologic disturbances; interrupt treatment and begin medical management, including management of hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disorders: Thyroid dysfunction (eg, hypothyroidism, hyperthyroidism, thyroiditis) may occur. Hyperthyroidism, sometimes followed by hypothyroidism, has also been reported. Monitor thyroid function at baseline and monitor for signs/symptoms of thyroid dysfunction during treatment. Patients not receiving thyroid hormone replacement therapy at sunitinib initiation should be monitored (TSH) every 4 weeks for 4 months and then every 2 to 3 months; those patients already receiving levothyroxine prior to initiating sunitinib should have TSH monitored every 4 weeks until levels and levothyroxine dose are stable, then monitor every 2 months (Hamnvik 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic microangiopathy: Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome), sometimes leading to renal failure or fatality, has been reported with sunitinib, both as monotherapy and in combination with bevacizumab. Discontinue sunitinib if thrombotic microangiopathy develops; effects may be reversible after discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Tumor lysis syndrome (TLS), including fatalities, has been reported, predominantly in patients with RCC or GIST. Risk for TLS is higher in patients with a high tumor burden prior to treatment; monitor closely. Correct clinically significant dehydration and treat high uric acid levels prior to initiation of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Wound healing complications: Impaired wound healing has been reported with sunitinib; temporarily withhold treatment for patients undergoing major surgical procedures. The optimal time to resume treatment after a procedure has not been determined; the decision to resume sunitinib following a major surgical procedure should be based on clinical judgement of recovery from surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal insufficiency: An increased incidence of fatigue, thyroid dysfunction and treatment-induced hypertension was reported in patients with renal insufficiency (CrCl &le;60 mL/minute) who received sunitinib for the treatment of renal cell cancer (Gupta 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Dosing schedules vary by indication; some treatment regimens are continuous daily dosing; other treatment schedules are daily dosing for 4 weeks of a 6-week cycle (4 weeks on, 2 weeks off).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525560\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525559\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10305&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May increase the serum concentration of SUNItinib. Applicable Isavuconazonium considerations are addressed in separate monographs. Management: Consider a reduced dose of sunitinib (minimum of 37.5 mg daily) during concomitant use. Concurrent use with itraconazole is not recommended per itraconazole labeling.<b> Exceptions: </b>Isavuconazonium Sulfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bevacizumab: SUNItinib may enhance the adverse/toxic effect of Bevacizumab. Specifically, the risk for a specific form of anemia, microangiopathic hemolytic anemia (MAHA), may be increased. Bevacizumab may enhance the hypertensive effect of SUNItinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Angiogenesis Inhibitors (Systemic) may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of SUNItinib. Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Systemic): May decrease the serum concentration of SUNItinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of SUNItinib. Management: Advise patients to avoid consuming grapefruit and grapefruit juice during sunitinib treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiCARdipine: May increase the serum concentration of SUNItinib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of SUNItinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: May enhance the adverse/toxic effect of SUNItinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525563\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Grapefruit juice may increase the levels/effects of sunitinib. Food has no effect on the bioavailability of sunitinib. Management: Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525544\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Based on animal reproduction studies and its mechanism of action, sunitinib may cause fetal harm if administered to a pregnant woman. Because sunitinib inhibits angiogenesis, a critical component of fetal development, adverse effects on pregnancy would be expected. Obtain a pregnancy test prior to treatment initiation in women of reproductive potential; effective contraception should be used during treatment and for at least 4 weeks after the last sunitinib dose. Male patients with female partners of reproductive potential should use effective contraception during treatment and for 7 weeks after the last sunitinib dose. Male and female fertility may be affected.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525547\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if sunitinib is present in human milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for at least 4 weeks after the last sunitinib dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525566\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2526131\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelets (prior to each treatment cycle and if indicated during treatment), liver function tests (baseline, with each cycle and if clinically indicated), serum chemistries including magnesium, phosphate, calcium, and potassium (prior to each treatment cycle), blood glucose levels (regularly during and following discontinuation of treatment), urinalysis (for proteinuria development or worsening); pregnancy test (prior to treatment in females of reproductive potential); LVEF at baseline (and periodic with cardiac risk factors), consider ECG (12-lead; baseline and periodic), monitor blood pressure routinely (Armenian 2017); monitor for signs/symptoms of HF during treatment; consider periodic LVEF evaluations; consider dental exam prior to treatment initiation; monitor for symptoms of hypothyroidism, hyperthyroidism, or thyroiditis; signs/symptoms of bleeding/hemorrhage, hypoglycemia, dermatologic toxicity. Monitor adherence.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid function testing (Hamnvik, 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preexisting levothyroxine therapy: Obtain baseline TSH levels, then monitor every 4 weeks until levels and levothyroxine dose are stable, then monitor every 2 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Without preexisting thyroid hormone replacement: TSH at baseline, then every 4 weeks for 4 months, then every 2-3 months</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525975\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Sunitinib exhibits antitumor and antiangiogenic properties by inhibiting multiple receptor tyrosine kinases, including platelet-derived growth factors (PDGFR&alpha; and PDGFR&beta;), vascular endothelial growth factors (VEGFR1, VEGFR2, and VEGFR3), FMS-like tyrosine kinase-3 (FLT3), colony-stimulating factor type 1 (CSF-1R), and glial cell-line-derived neurotrophic factor receptor (RET).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525977\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>/F: 2230 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Sunitinib: 95%; SU12662: 90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; primarily metabolized by CYP3A4 to the N-desethyl metabolite SU12662 (active)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: Sunitinib: 40 to 60 hours; SU12662: 80 to 110 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 6 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (61%); urine (16%) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5685504\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Sutent Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (28): $5,865.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (28): $11,731.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">37.5 mg (28): $17,597.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (28): $20,423.04</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539968\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Sunitix (BD);</li>\n      <li>Sutene (KR);</li>\n      <li>Sutent (AE, AR, AT, AU, BB, BE, BG, BH, BR, BZ, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IS, IT, JO, JP, KW, LB, LK, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UA, UY, VE, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Appleby L, Morrissey S, Bellmunt J, et al. Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices. <i>Hematol Oncol Clin North Am. </i>2011;25(4):893-915.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/21763973/pubmed\" target=\"_blank\" id=\"21763973\">21763973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi: 10.1200/JCO.2016.70.5400.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/27918725/pubmed\" target=\"_blank\" id=\"27918725\">27918725</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cella D, Michaelson MD, Bushmakin AG, et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. <i>Br J Cancer. </i>2010;102(4):658-664.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/20104222/pubmed\" target=\"_blank\" id=\"20104222\">20104222</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Cohen.2008\"></a>Cohen EE, Needles BM, Cullen KJ, et al. Phase 2 Study of Sunitinib in Refractory Thyroid Cancer. <i>J Clin Oncol. </i>2008;26(Supp):6025 [abstract 6025 from 2008 ASCO Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Costero O, Picazo ML, Zamora P, Romero S, Martinez-Ara J, Selgas R. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. <i>Dial Nephrol Transplant. </i>2010;25(3):1001-1003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/20019017/pubmed\" target=\"_blank\" id=\"20019017\">20019017</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Demetri GD, van Oosterom AT, Garret CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. <i>Lancet.</i> 2006;368(9544):1329-1338.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/17046465/pubmed\" target=\"_blank\" id=\"17046465\">17046465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feldt S, Sch&uuml;ssel K, Quinzler R, et al. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. <i>Eur J Cancer</i>. 2012;48(7):974-981.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/22382202/pubmed\" target=\"_blank\" id=\"22382202\">22382202</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gallucci G, Tartarone A, Tocchetti CG, et al. Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature. <i>Future Oncol</i>. 2013;9(1):127-133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/23252570/pubmed\" target=\"_blank\" id=\"23252570\">23252570</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. <i>Eur J Cancer.</i> 2009a;45(11):1959-1968.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/19282169/pubmed\" target=\"_blank\" id=\"19282169\">19282169</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19451429\"></a>George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. <i>J Clin Oncol.</i> 2009b;27(19):3154-3160.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/19451429/pubmed\" target=\"_blank\" id=\"19451429\">19451429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta S, Parsa VB, Heilbrun LK, et al. Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. <i>Anticancer Drugs. </i>2011;22(8):794-800.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/21799472/pubmed\" target=\"_blank\" id=\"21799472\">21799472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. <i>J Natl Cancer Inst.</i> 2011; 103(21):1572-1587.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/22010182/pubmed\" target=\"_blank\" id=\"22010182\">22010182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. <i>Oncologist.</i> 2008;13(9):1001-1011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/18779536/pubmed\" target=\"_blank\" id=\"18779536\">18779536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. <i>J Clin Oncol. </i>2009;27(22):3584-3590.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/19487381/pubmed\" target=\"_blank\" id=\"19487381\">19487381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell cancer. <i>N Engl J Med. </i>2007;356(2):115-124.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/17215529/pubmed\" target=\"_blank\" id=\"17215529\">17215529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Motzer RJ, Michaelson MD, and Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor, in patients with metastatic renal cell cancer. <i>J Clin Oncol</i>. 2006a;24(1):16-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/16330672/pubmed\" target=\"_blank\" id=\"16330672\">16330672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. <i>JAMA</i>. 2006b;295(21):2516-2524. doi: 10.1001/jama.295.21.2516.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/16757724/pubmed\" target=\"_blank\" id=\"16757724\">16757724</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Navid F, Christensen R, Minkin P, Stewart CF, Furman WL, Baker S. Stability of sunitinib in oral suspension. <i>Ann Pharmacother. </i>2008;42(7):962-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/18577759/pubmed\" target=\"_blank\" id=\"18577759\">18577759</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel TV, Morgan JA, Demetri GD, et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. <i>J Natl Cancer Inst</i>. 2008;100(4):282-284.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/18270341/pubmed\" target=\"_blank\" id=\"18270341\">18270341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Ravaud.2008\"></a>Ravaud A, de la Fouchardiere C, Courbon F, et al. Sunitinib in patients with refractory advanced thyroid cancer: The THYSU Phase II Trial. <i>J Clin Oncol.</i> 2008;26(Supp):6058 [abstract 6058 from 2008 ASCO Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. <i>N Engl J Med</i>. 2016;375(23):2246-2254. doi: 10.1056/NEJMoa1611406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/27718781/pubmed\" target=\"_blank\" id=\"27718781\">27718781</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. <i>N Engl J Med. </i>2011;364(6):501-513.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/21306237/pubmed\" target=\"_blank\" id=\"21306237\">21306237</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <i>J Oral Maxillofac Surg</i>. 2014;72(10):1938-1956. doi: 10.1016/j.joms.2014.04.031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/25234529/pubmed\" target=\"_blank\" id=\"25234529\">25234529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sutent (sunitinib) [prescribing information]. New York, NY: Pfizer Labs; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sutent (sunitinib) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zastrow S, Froehner M, Platzek I, et al. Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis. <i>Urology.</i> 2009;73(4):868-870.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sunitinib-drug-information/abstract-text/19167044/pubmed\" target=\"_blank\" id=\"19167044\">19167044</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10305 Version 178.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F10432264\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F2525534\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5558623\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F2525538\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F2526125\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2526126\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F2526127\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F2526128\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F6825472\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F2526134\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F2525536\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F10437825\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2526129\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132824\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2525541\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25470558\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3402058\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2525552\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F2525548\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2525549\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F2525560\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2525559\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F2525563\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2525544\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2525547\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F2525566\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2526131\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2525975\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F2525977\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5685504\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539968\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10305|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sunitinib-patient-drug-information\" class=\"drug drug_patient\">Sunitinib: Patient drug information</a></li></ul></div></div>","javascript":null}